No Longer Business as Usual: Critical Changes in Investment and IP Strategy for Life Sciences

Is your life sciences company ready to address new IP, regulatory, and investment models?

Join Foley and QB3 for No Longer Business as Usual: Critical Changes in Investment and IP Strategy for LIfe Sciences. During this full-day conference, financial advisors, industry executives and thought-leaders, and legal counsel will present four interactive panels and provide insight on critical business, regulatory, and legal issues to help you address the critical changes occurring as a result of landmark changes happening within the industry.

The program includes:

Opening keynote presentation, “The Changing Face of Life Science” by Regis B. Kelly, Director of QB3 at the University of California

Panel #1: Financing Early-Stage Personalized Medicine Technologies

• What personalized medicine technologies are being financed?


• Drafting a robust and comprehensive business model


• Stories from successful venture-backed companies


• Obtaining lines of credit, term loans, and venture debt

Speakers: Jeff Karan, Founder & Senior Partner, Woodside Capital; Jennifer Friel Goldstein, Managing Director, Life Sciences, Silicon Valley Bank; Paul Quadros, Life Sciences/Biotech Committee, Band of Angels 

Panel #2: The Aftermath of Myriad: IP Protection at Home and Abroad

• Implementation of Myriad at the USPTO


• Re-aligning your IP portfolio in lieu of Myriad


• Patenting life science technologies abroad


• Myriad litigation: What is at stake?

Speakers: Dianna DeVore, Vice President, Intellectual Property and Legal Affairs, Ariosa Diagnostics, Inc.; Kristel Schorr, Partner, Foley & Lardner

Moderator: Antoinette Konski, Partner, Foley & Lardner

Featured Lunch Keynote Discussion: Standing Out in the Crowd: Business Development, Product Positioning and Marketing Techniques for Early to Mid-Stage Life Science Companies

• Developing a marketing and product positioning plan


• Building relationships with funding sources, CROs and manufacturers


• Strategically positioning your product to potential partners


• Innovative lead generation techniques

Speaker: Asa Cox, Founder & CEO, Founder & President, Generic Pharma 2.0

Moderator: Anjan Chatterji, Public Affairs Director — Healthcare Economics, Foley & Lardner

Panel #4: No Longer Business as Usual: Critical Regulatory Updates

• What is expected to be announced in the final guidance on in vitro companion diagnostic devices?


• Biosimilars: What’s close enough?


• mHealth Technologies: What is expected with the FDA’s final guidance schedules to be released by the end of the year?

Speakers: Sue Preston, Consultant, Alacrita; Alice M. Varga, MS, MA, Vice President, Regulatory and Quality Assurance, Oxigene,
Inc.

Moderator: David Rosen, Partner, Foley & Lardner LLP

Panel #3: The Utilization and Protection of Big Data in the Era of Personalized Medicine

With the potential to transform drug discovery, clinical research and the delivery of effective healthcare outcomes, big data is a critical component in promoting personalized health care. During this discussion panel members will address the
following:

• How can EHR’s help to facilitate personalized medicine becoming mainstream in clinical practice


• Business cases for the use of patient data


• Big data and analytics: what are the technology platforms that are most likely to have the biggest impact on our ability to conduct bigger, faster and more precise analytics?


• How can companies protect their data and analytics

Speakers: Tahir A. Mahmood, PhD, Booz Allen Hamilton; Marc Morley, Partner, Foley & Lardner; Invited: Samarth KulKarni, PhD., McKinsey & Company

Moderator: Richard Kaufman, Partner, Foley & Lardner

Closing Address by Stephanie Marrus, Director of the Entrpreneurship Center, UCSF

This conference is complimentary; however, registration is required. To register, please use the Register Now button above. For additional information, please contact Delia Dai at [email protected].